PFA3 Antibody

What is pFA3 and what are its primary research applications?

pFA3 (Plasmid #46790) is a yeast expression vector designed specifically to express ATPase-inactive Fun30 in Saccharomyces cerevisiae. The plasmid contains the Fun30 gene with a point mutation that replaces lysine at position 603 (AAA) with arginine (AGA), creating an ATPase-inactive version of the protein . This plasmid is particularly valuable for studying the ATP-dependent chromatin remodeling functions of Fun30 through a loss-of-function approach.

The primary research applications include:

• Investigating Fun30's role in chromatin structure maintenance

• Studying ATP-dependent chromatin remodeling mechanisms

• Analyzing how ATP hydrolysis affects Fun30's biological functions

• Creating dominant-negative models to understand Fun30-related pathways

What expression system does pFA3 use and how should it be handled?

pFA3 utilizes the pYES2.1/V5-His/lacZ backbone from Invitrogen, which provides galactose-inducible expression in yeast . The expression system includes:

• Promoter: GAL1 (PGAL1) for strong, regulated expression

• Tags: C-terminal V5 and 6xHis tags for detection and purification

• Selection marker: URA3 for selection in yeast

• Bacterial resistance: Ampicillin (100 μg/mL) for propagation in bacteria

Handling recommendations:

• Propagate in Top10 E. coli strains at 37°C

• Use ura3-deficient yeast strains for selection

• Store plasmid preparations at -20°C for long-term storage

• Verify plasmid integrity through restriction enzyme analysis before use

How does antibody detection work for proteins expressed from pFA3?

Proteins expressed from pFA3 can be detected using commercial antibodies against the V5 or 6xHis epitope tags . This approach offers several advantages:

• Standardized detection: Commercially validated anti-V5 or anti-His antibodies ensure consistent results

• Flexibility in applications: These antibodies are optimized for various methods including Western blotting, immunoprecipitation, and immunofluorescence

• Distinguishing from endogenous protein: Tag-based detection allows differentiation between the expressed mutant and endogenous wild-type protein

For most rigorous experimental controls, consider using both tag-specific antibodies and protein-specific antibodies (when available) to confirm expression and localization.

What controls should be included when working with pFA3-expressed proteins?

Robust experimental design with appropriate controls is essential when working with pFA3:

These controls help distinguish between effects caused by the ATPase-inactive mutation versus those resulting from expression system artifacts.

How should I optimize induction conditions for pFA3 in yeast?

The GAL1 promoter in pFA3 requires careful optimization of induction conditions:

• Pre-culture conditions: Grow cells in glucose-containing medium to mid-log phase (OD600 ~0.6-0.8)

• Media transition: Wash cells thoroughly (3× in sterile water) to remove all glucose

• Induction medium options:

  • Standard induction: 2% galactose in YEP or synthetic complete medium lacking uracil

  • Reduced expression: 0.1-0.5% galactose mixed with raffinose (which doesn't repress the promoter)

• Time course consideration: Monitor expression at 4, 8, 12, and 24 hours post-induction to determine optimal expression time

• Temperature effects: Standard induction at 30°C, but lower temperatures (25°C) may improve protein folding

For phenotypic studies, remember that overexpression itself may cause artifacts. Consider using lower galactose concentrations or shorter induction times to achieve near-physiological expression levels.

How does the K603R mutation affect Fun30 function and what experimental considerations does this entail?

The K603R mutation in pFA3 targets the ATP-binding site of Fun30, rendering it catalytically inactive while preserving protein structure . This mutation has specific implications:

• Molecular consequences:

  • Disrupts ATP hydrolysis but not ATP binding

  • Preserves protein-protein interactions in most cases

  • Maintains chromatin association but prevents remodeling

• Experimental considerations:

  • May act as a dominant negative by competing with wild-type protein

  • Useful for dissecting ATP-dependent versus ATP-independent functions

  • Can sequester interaction partners without completing the remodeling cycle

When designing experiments, consider that the mutant protein may have unexpected gain-of-function effects through prolonged association with substrates that it can bind but not remodel.

How can pFA3 be integrated with antibody-based approaches to study chromatin dynamics?

Combining pFA3 expression with antibody-based techniques creates powerful experimental systems:

• Chromatin immunoprecipitation (ChIP):

  • Use anti-V5 or anti-His antibodies to selectively precipitate chromatin bound by the mutant protein

  • Compare binding profiles between wild-type and ATPase-inactive Fun30 to identify remodeling-dependent and independent interactions

• Proximity-based labeling:

  • Modify pFA3 to express Fun30(K603R) fused to BioID or APEX2

  • Identify proteins that interact with Fun30 in its ATP-bound state

• Microscopy applications:

  • Immunofluorescence using tag-specific antibodies can reveal altered localization patterns

  • Super-resolution microscopy combined with specific antibodies can detect structural changes in chromatin organization

These approaches help dissect the mechanistic basis of Fun30's chromatin remodeling activities by separating binding events from remodeling events.

What insights can ATPase-inactive Fun30 provide about DNA repair pathways?

The ATPase-inactive Fun30 expressed from pFA3 has been instrumental in understanding DNA repair mechanisms:

• Double-strand break (DSB) resection:

  • ATPase-inactive Fun30 binds to DSB sites but fails to facilitate long-range resection

  • This approach revealed that ATP hydrolysis is required for removing nucleosomes during resection

• Checkpoint regulation:

  • Expression of ATPase-inactive Fun30 causes prolonged checkpoint activation

  • Helps separate Fun30's roles in initial checkpoint triggering versus recovery

• Recombination dynamics:

  • Comparing cells expressing wild-type versus ATPase-inactive Fun30 reveals ATP-dependent steps in homologous recombination

  • Specifically helpful in understanding how chromatin barriers are overcome during DNA repair

When designing DNA repair experiments, consider using DNA damage agents with different mechanisms (e.g., MMS, phleomycin, hydroxyurea) to comprehensively assess Fun30's role in various repair pathways.

How does antibody selection impact experimental outcomes when studying pFA3-expressed proteins?

Antibody selection is critical for accurate analysis of proteins expressed from pFA3:

• Tag-specific versus protein-specific antibodies:

  • Tag-specific antibodies (anti-V5, anti-His) detect only the expressed protein

  • Protein-specific antibodies detect both endogenous and expressed protein, requiring careful interpretation

• Cross-reactivity considerations:

  • When assessing protein interactions, validate antibody specificity to avoid false positives

  • Use blocking peptides or antigen competition assays to confirm binding specificity

• Application-specific optimization:

  • Western blotting: Optimize antibody concentration, incubation time, and blocking conditions

  • Immunofluorescence: Test fixation methods that preserve epitope accessibility

  • ChIP: Validate antibody lot for immunoprecipitation efficiency and specificity

For maximal reproducibility, maintain detailed records of antibody sources, catalogs numbers, lot numbers, and optimized conditions for each application.

What are common challenges when expressing proteins from pFA3 and how can they be addressed?

Expression of ATPase-inactive Fun30 from pFA3 can present several challenges:

For persistent expression problems, consider modifying the construct by using a weaker promoter or creating a genomic integration with physiological regulation.

How can I verify the expression and functionality of the ATPase-inactive Fun30?

Comprehensive verification of expression and functionality requires multiple approaches:

• Expression verification:

  • Western blotting with anti-V5 or anti-His antibodies

  • Flow cytometry with fluorescently labeled antibodies if constructing a cell-based assay

  • Mass spectrometry to confirm protein identity and modification state

• Functionality assessment:

  • ATPase assays (negative control - should show minimal activity)

  • Chromatin association assays (should bind but not remodel)

  • DNA binding assays (electrophoretic mobility shift assay or fluorescence anisotropy)

• Structural integrity confirmation:

  • Circular dichroism spectroscopy to assess secondary structure

  • Limited proteolysis to compare digestion patterns between wild-type and mutant

  • Thermal shift assays to evaluate protein stability

A systematic approach combining these methods will provide robust validation of your experimental system before proceeding to more complex analyses.